文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

5-羟色胺转运体基因多态性与SSRI耐受性的药物遗传学证据综述

Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.
PubMed 文献 · Pharmacotherapy · 2017-08-11

本文系统综述约15年间关于SLC6A4基因5-HTTLPR和STin2多态性与选择性5-羟色胺再摄取抑制剂(SSRI)耐受性表型关系的研究。STin2研究稀少且结果矛盾。

要点

  • 5-HTTLPR S等位基因可能预测SSRI治疗中不良反应负担增加。
  • 证据最支持S等位基因与抗抑郁药诱发躁狂及胃肠道不良事件相关。
  • STin2多态性研究稀少且结果矛盾,尚不能用于临床。

核心结论

  • 5-HTTLPR低表达S等位基因通常与SSRI治疗期间更大的不良反应负担相关,但该效应似乎特定于某些类别的不良事件。
  • 5-HTTLPR S等位基因与抗抑郁药诱发躁狂和胃肠道不良事件的关联证据最具说服力。
  • STin2多态性研究稀少且结果矛盾。
  • 5-羟色胺转运体基因型的临床效用尚未明确,最终取决于基因型对SSRI耐受性和疗效的双重影响。

研究设计与样本

  • 本文为药物遗传学证据综述,系统检索PubMed、Cochrane CENTRAL、PsycINFO和PharmGKB四个在线数据库。
  • 检索策略纳入SLC6A4基因5-HTTLPR和STin2多态性相关文章,并补充精神药理学、不良反应和耐受性概念术语。
  • 另核查人类基因突变数据库以获取额外参考文献。

主要发现

  • 部分研究报告无关联,偶尔报告相反关联,但低表达5-HTTLPR S等位基因通常与SSRI治疗期间更重的不良反应负担相关。
  • 抗抑郁药诱发躁狂和胃肠道不良事件的研究提供了最令人信服的证据。
  • STin2研究稀疏且发现相互矛盾。

临床怎么用

  • 目前5-羟色胺转运体基因型对SSRI耐受性的临床效用尚未明确,暂不能据此常规指导用药选择。
  • 临床应关注5-HTTLPR S等位基因携带者使用SSRI时可能面临更高的不良反应负担,尤其是抗抑郁药诱发躁狂和胃肠道不良事件。

局限性

  • 解读该证据体存在局限与挑战,包括检测误差、基因型分组不一致。
  • 种族在关联中的作用以及研究方法学差异也构成局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for mood and anxiety disorders. The common mechanism of drugs in this class is antagonism of the serotonin transporter. Within the serotonin transporter gene SLC6A4, two polymorphic sites termed 5-HTTLPR and STin2 are proposed to have functional consequences and thus have been attractive candidates for pharmacogenetic studies of SSRI efficacy and tolerability. This review summarizes approximately 15 years of study of these polymorphisms as they relate to SSRI tolerability phenotypes. Four online databases (PubMed, Cochrane CENTRAL, PsycINFO, and PharmGKB) were searched for articles on polymorphisms of SLC6A4 including 5-HTTLPR and STin2 by using a systematic approach. Specific and general psychopharmacology terms, along with adverse effect and tolerability concepts, added to the search strategy. The Human Gene Mutation Database was checked for additional references. Forty studies met the inclusion criteria. While null and occasionally opposite associations are reported, the low expression 5-HTTLPR S allele is generally associated with greater adverse drug reaction burden during SSRI therapy. The most convincing evidence is in studies of antidepressant-induced mania and gastrointestinal adverse events. Studies of STin2 are sparse and have conflicting findings. In conclusion, the S allele of 5-HTTLPR may be predictive of increased adverse event burden, and this effect appears specific to certain classes of adverse events. Limitations and challenges in interpreting this body of evidence include assay errors, dissimilar grouping of genotypes, the role of ethnicity in associations, and study methodological differences. The clinical utility of serotonin transporter genotypes is not yet delineated but will ultimately depend on genotypic effects on both tolerability and efficacy of SSRIs.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Zhu J, Klein-Fedyshin M, Stevenson JM, et al. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence. Pharmacotherapy. 2017. PMID: 28654193. doi:10.1002/phar.1978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。